The University of Chicago Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Talamonti, Mark
One or more keywords matched the following items that are connected to Talamonti, Mark
Item TypeName
Concept Psoriasis
Academic Article Long-term treatment of plaque psoriasis with efalizumab: an Italian experience.
Academic Article Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
Academic Article Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension.
Academic Article The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab.
Academic Article Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab.
Academic Article Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.
Academic Article HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis.
Academic Article Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis.
Academic Article Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
Academic Article Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature.
Academic Article Brodalumab for the treatment of psoriasis.
Academic Article Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy.
Academic Article Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience.
Academic Article Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
Search Criteria
  • Psoriasis